PLAUR and ganglioneuroma: In the remaining 92 study subjects with eGFR ≥60 mL/min a significant difference in suPAR levels [ng/mL] between FSGS and other GN patients (5.05 ± 1.35 vs. 2.91 ± 0.94 ng/mL, p = 0.001 for the suPARnosticTM assay and 2.91 ± 0.48 vs. 2.61 ± 0.49 ng/mL, p = 0.036 for the Quantikine Human uPAR ELISA Kit) was confirmed.